Capricor Therapeutics to present at upcoming investor conferences
Capricor Therapeutics announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference and the Oppenheimer CNS and Neuro-Muscular Summit on June 10. A webcast of the Goldman Sachs fireside chat will be available on the company's website.
*this image is generated using AI for illustrative purposes only.
Capricor Therapeutics, a biotechnology company developing cell and exosome-based therapeutics for rare diseases, announced that senior management will participate in two upcoming investor conferences on Wednesday, June 10. The company will engage with investors to discuss its lead product candidate, Deramiocel, and its proprietary StealthX exosome platform.
The company is scheduled to attend the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL. Management will conduct a fireside chat and investor meetings at 10:00 a.m. ET. A live webcast of the session will be accessible, with a replay available in the Investors section of the Capricor Therapeutics website following the event.
Additionally, Capricor Therapeutics will participate in the Oppenheimer CNS and Neuro-Muscular Summit, also taking place in Miami, FL. Senior management will take part in an industry panel and hold investor meetings throughout the day.
Conference Schedule
| Conference | Location | Date & Time | Activity |
|---|---|---|---|
| Goldman Sachs 47th Annual Global Healthcare Conference | Miami, FL | Wednesday, June 10, 10:00 a.m. ET | Fireside chat and investor meetings |
| Oppenheimer CNS and Neuro-Muscular Summit | Miami, FL | Wednesday, June 10 | Industry panel and investor meetings |
Capricor Therapeutics focuses on advancing therapies for rare diseases, with Deramiocel in late-stage development for Duchenne muscular dystrophy (DMD). The company is also developing its StealthX platform for targeted delivery of therapeutics across various diseases.
What key updates on Deramiocel's late-stage development for DMD are expected to be shared during these conferences?
How might investor interest in Capricor's StealthX platform evolve following these presentations?
Could these conferences lead to new partnerships or collaborations for Capricor in the rare disease space?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
